Xaluritamig

DB18137InvestigationalProtein Based Therapies

Xaluritamig is a novel humanized bispecific T cell recruiting antibody cross-reactive to human and nonhuman primate STEAP1 and CD3.

Mechanism: Pharmacologically active on T-cell surface glycoprotein CD3 and STEAP1 protein
Curator reviewed
Also known as: Immunoglobulin G1 Fab fragment [218-lysine], anti-(human metalloproteinase STEAP1) (human-Mus musculus clone 2F3.013 N67Q γ1-chain) fusion protein with peptide linker (GGGGS)2 fusion protein with immunoglobulin anti-(human CD3 antigen) (human-Mus muscul · immunoglobulin G1-scFv-CH/G1-kappa, anti-[Homo sapiens STEAP1 (STEAP family member 1, six transmembrane epithelial antigen of the prostate 1, STEAP1 metalloreductase) and anti-[Homo sapiens CD3, bispecific, trivalent
Code names: AMG-509

Resolves to

Compound

Targets

What you can answer from here — as of July 08, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

9Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Xaluritamig, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.